Novel Gene Therapy for Enhancing Anti-Tumor Immunity.
Abstract
This study aims to genetically modify the tumor cells and use them to induce efficient and vigorous anti-tumor immunity. Murine mammary carcinoma cell lines, 66.1 (metastatic and non-immunogenic) and 410.4 (non-metastatic and immunogenic) are used in the initial studies. To investigate whether or not costimulation of CD8+ T cells is sufficient to induce tumor rejection, the wild type 66.1 tumor cells (66.l/WT) were transfected with B7.I cDNA and stable lines and clones that constitutively express B7.I protein (66.1'B7.I+) were generated. Subcutaneous injection of live 66. 1'B7.I+ tumor cells into Balbic mice showed significant delay in the growth compared to 66.1/WT tumor cells. However, complete rejection was not seen, indicating that activation of CD8+ T cells alone is not sufficient to-induce tumor rejection. Further studies are under way wherein transfectants expressing both B7.I and class II MHC molecules will be used to induce tumor immunity in the syngenic host. These transfectants will help to understand the role of CD4+ T helper cells and CD8+ cytotoxic T cells in the induction of anti-tumor immunity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 26, 1995
- Accession Number
- ADA300057
Entities
People
- Sivasubramanian Baskar
Organizations
- University of Maryland, Baltimore County